Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents.

Abstract

There are limited data on the long-term stent-related adverse events as related to the duration of dual antiplatelet therapy (DAPT) in second-generation (G2) drug-eluting stents (DES) compared with first-generation (G1) DES. This study sought to compare the long-term stent-related outcomes of G2-DES with those of G1-DES. The study group consisted of 15,009 patients who underwent their first coronary revascularization with DES from the CREDO-Kyoto PCI/CABG (Coronary Revascularization Demonstrating Outcome Study in Kyoto Percutaneous Coronary Intervention/Coronary Artery Bypass Grafting) Registry Cohort-2 (first-generation drug-eluting stent [G1-DES] period; n=5,382) and Cohort-3 (second-generation drug eluting stent [G2-DES] period; n=9,627). The primary outcome measures were definite stent thrombosis (ST) and target vessel revascularization (TVR). The cumulative 5-year incidences of definite ST and TVR were significantly lower in the G2-DES group than in the G1-DES group (0.7% vs 1.4%; P< 0.001; and 16.2% vs 22.1%; P< 0.001, respectively). The lower adjusted risk of G2-DES relative to G1-DES for definite ST and TVR remained significant (HR: 0.53; 95%CI: 0.37-0.76; P< 0.001; and HR: 0.74; 95%CI: 0.68-0.81; P< 0.001, respectively). In the landmark analysis that was based on the DAPT status at 1 year, the lower adjusted risk of on-DAPT status relative to off-DAPT was significant for definite ST beyond 1 year in the G1-DES stratum (HR: 0.42; 95%CI: 0.24-0.76; P=0.004) but not in the G2-DES stratum (HR: 0.66; 95%CI: 0.26-1.68; P=0.38) (P interaction=0.14). G2-DES compared with G1-DES were associated with a significantly lower risk for stent-related adverse events, including definite ST and TVR. DAPT beyond 1 year was associated with a significantly lower risk for very late ST ofG1-DES but not for that of G2-DES.